Drug being studied for ovarian cancer proving successful against COVID-19 Researchers at NAU’s COVID-19 Testing Center (CTSC) have been working on treatments for COVID-19 since April 2020. Now, scientists have published their success with a drug called Stenoparib. Currently, Stenoparib is in phase two clinical trials to treat ovarian cancer, but those at CTSC are finding success in combating the coronavirus. “It acts on the host cell, rather than the virus itself,” Christopher Todd French, PhD, director of the CTSC, said. Stenoparib most helpful when combined with Remdesivir After finding Stenoparib to be successful in inhibiting the virus, French said they turned to see how it would work when combined with other drugs.